All News
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies
Inhibition of B cell activating factor (BAFF) and B cell depletion are the two most evaluated strategies over the last 15 years in the field of SLE therapeutics, with licensing of belimumab and off-label use of rituximab.
Read Article
« CAR T cells can change the therapeutic scenario: a short treatment for a prolonged efficacy » says G. Schett
Are we finally looking at the « visionary scenario »?
@RheumNow #EULAR2024 https://t.co/tzfDormeIl
Aurelie Najm AurelieRheumo ( View Tweet)
Pt with LN, endocarditis, pericarditis, arthritis, rash failed CTX, MMF, BEL, and SOC. She is 1000 days post CAR-T cell. Off immunomodulating drugs. #SLE in remission clinically and serologically. - Dr G Schett #EULAR24 @RheumNow https://t.co/3vdMtO6VWI
TheDaoIndex KDAO2011 ( View Tweet)
Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek
Dr. Antoni Chan synovialjoints ( View Tweet)
Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek
Dr. Antoni Chan synovialjoints ( View Tweet)
RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX)
870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
Grappa difficult to treat PsA meeting - SLR, Patient & rheumo survey, definition eg - fail 1 csDMARD & 2 bDMARDs different MOA - names matter suggest ditch « difficult » for « refractory » @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
Humira Clobbers Biosimilars in Battle for Part D Coverage
d
Medpage Today
Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar versions currently approved, researchers found.
Read Article
Medicare & Optum claims data study of 2851 #RA pts w/ breast cancer (BC). In 3 mos before BC 27028% received bDMARDs. W/in 1st 3 yrs post-BC Dx 24-26% were receiving bDMARDs. 70% of RA pts on steroids without change w/ time https://t.co/51NcXv0xyc https://t.co/461NZiFvDO
Dr. John Cush RheumNow ( View Tweet)
Cannabis Use is Common, But is it Safe?
Two current JAMA reports suggest that cannabis use is not only common, but that if heavily used may increase mortality rates.
Read Article
Forbes on the future of CAR-T cell therapy - A Gamechanger For Autoimmune Diseases. Innovation, costs, more trials and regulatory differences for autoimmune (vs cancer) patietns? https://t.co/6Siv0Y1GDB https://t.co/Mmbh4ER7vf https://t.co/j8bgn8DkLw
Dr. John Cush RheumNow ( View Tweet)
Forbes on the future of CAR-T cell therapy - A Gamechanger For Autoimmune Diseases. Innovation, costs, more trials and regulatory differences for autoimmune (vs cancer) patietns? https://t.co/6Siv0Y1GDB https://t.co/Mmbh4ER7vf https://t.co/j8bgn8DkLw
Links:
Dr. John Cush RheumNow ( View Tweet)
Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/NMWtHB94Pi https://t.co/ok43pnagFg
Links:
Dr. John Cush RheumNow ( View Tweet)
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis
A single center study demonstrates that biologic treatment of PsO significantly reduces the likelihood of PsA development; suggesting a role for more aggressive treatment of PsO.
https://t.co/VHk2KEsP8d https://t.co/1r4zVAzrMw
Dr. John Cush RheumNow ( View Tweet)
Ramosetron,a 5-HT3 recept antagonist used for post-op N/V,t has been used for adjunctive pain Rx & IBS. An 80 FM pt DBRCT tested PBO vs Ramosetron (.3 mg/day IV x5d). @d5 had signif better VAS pain (1.18 vs 0.54, p< 0.05), but didnt persist till day 28 https://t.co/0ABduv8Nlq https://t.co/WGlxIhst1o
Dr. John Cush RheumNow ( View Tweet)
Do you have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/qvVEUoNYi5 https://t.co/duw6jg5xpp
Dr. John Cush RheumNow ( View Tweet)
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis
A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO.
Preliminary results of ph IIB ORIGIN trial of placebo vs Atacicept (binds BAFF & APRIL)in 166 pts w/ IgA Nephropathy (Berger’s Dz) Gd-IgA1, hematuria, and UPCR (vs PBO) in the blinded 1st 36 weeks of the trial. https://t.co/tPhCrSaSTC https://t.co/6HqGFtb1IE
Links:
Dr. John Cush RheumNow ( View Tweet)
Available online, open access:
A review of CAR-T call therapy in rheumatic disease by @RyuOhno06
See below diagram of CAR-T therapy mechanism in cancer.
https://t.co/WALWulEDkW https://t.co/k1FD0zHtWu
Seminars in Arthritis and Rheumatism seminarthrheum ( View Tweet)
Available online, open access:
A review of CAR-T call therapy in rheumatic disease by @RyuOhno06
See below diagram of CAR-T therapy mechanism in cancer.
https://t.co/WALWulEDkW https://t.co/k1FD0zHtWu
Seminars in Arthritis and Rheumatism seminarthrheum ( View Tweet)